| Home |
| Site Map |
| News Archives |
| Environmental Health News |
| Illness Research |
| Articles |
| Treatment Information |
| Useful Lab Tests |
| Find A Doctor |
| Chemical Avoidance |
| Allergen Reduction |
| Water Filtration |
| Treatments & Products |
| Books |
| Dr. Teitelbaum's Column |
| Gloria Gilbčre's Column |
| Sick Building Syndrome |
| Seasonal Affective Disorder |
| Lyme Disease |
| Lupus |
| Hypoglycemia |
| Electrical Sensitivity |
| Adrenal Fatigue |
| Hypothyroidism |
| Sleep Apnea |
| Restless Leg Syndrome |
| Celiac Disease |
| Water Filters |
| SAD Light Boxes |
| Hepa Air Purifiers |
| HEPA Vacuum Cleaners |
| Nutritional Supplements |
| Home Test Kits |
| Cleaning Products |
| Personal Care |
| LifeWave Patches |
|
|
| Research - Candida & Gut Dysbiosis Research | |
|
Helicobacter. 2008 Apr;13(2):127-34.
Inhibition of Helicobacter pylori infection in humans by Lactobacillus reuteri ATCC 55730 and effect on eradication therapy: a pilot study.
Francavilla R, Lionetti E, Castellaneta SP, Magistà AM, Maurogiovanni G, Bucci N, De Canio A, Indrio F, Cavallo L, Ierardi E, Miniello VL. Department of Biomedicina dell'Età Evolutiva, Università degli Studi di Bari, Bari, Italy. This e-mail address is being protected from spam bots, you need JavaScript enabled to view it
BACKGROUND: Several studies report an inhibitory effect of probiotics on Helicobacter pylori. Aim: To test whether Lactobacillus reuteri ATCC 55730 reduces H. pylori intragastric load in vivo, decreases dyspeptic symptoms, and affects eradication rates after conventional treatment.
MATERIALS AND METHODS: In a double-blind placebo-controlled study, 40 H. pylori-positive subjects were given L. reuteri once a day for 4 weeks or placebo. All underwent upper endoscopy, (13)C-urea breath test, and H. pylori stool antigen determination at entry and (13)C-urea breath test and H. pylori stool antigen (used as both qualitative and semiquantitative markers) after 4 weeks of treatment. Sequential treatment was administered subsequently to all.
RESULTS: In vivo, L. reuteri reduces H. pylori load as semiquantitatively assessed by both (13)C-urea breath test delta-value and H. pylori stool antigen quantification after 4 weeks of treatment (p < .05). No change was shown in patients receiving placebo. L. reuteri administration was followed by a significant decrease in the Gastrointestinal Symptom Rating Scale as compared to pretreatment value (p < .05) that was not present in those receiving placebo (p = not significant). No difference in eradication rates was observed.
CONCLUSIONS: L. reuteri effectively suppresses H. pylori infection in humans and decreases the occurrence of dyspeptic symptoms. Nevertheless, it does not seem to affect antibiotic therapy outcome.
Comments (0)
![]() Write comment
Discuss this article on the forums. (0 posts) |
|
| < Prev | Next > |
|---|
| searching for a doctor marie olene 11-12-08 23:42 |
| Skin Lesions Granuloma annulare Humminbyrd 11-05-08 20:39 |
| headaches, vertigo karenk 11-01-08 16:07 |
| All Canadians with MCS... LadyItchalot 10-20-08 04:42 |
| Skincare for those with Chemical Sensit... yayaba08 10-14-08 19:28 |
Subscribe to our newsletter and receive regular updates of our latest content: